Related Experiment Video
Updated: Jun 10, 2026
12:22
The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
Emerging molecular classification in renal cell carcinoma: implications for drug development
Kathryn E Hacker1, W Kimryn Rathmell
1Department of Genetics, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 450 West Drive, CB 7295, Chapel Hill, NC 27599, USA.
Targeted Oncology
|July 21, 2010
Summary
Identifying effective biomarkers is crucial for selecting targeted therapies in advanced renal cell carcinoma (RCC). Molecular subclassification of tumors may improve patient stratification and treatment selection for better outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Translational Medicine
Background:
- Targeted therapies have advanced treatment for advanced renal cell carcinoma (RCC).
- Current challenges include a lack of effective biomarkers to guide personalized treatment selection.
- Existing biomarkers for targeted therapies in advanced RCC have yielded equivocal results, necessitating further research.
Purpose of the Study:
- To address the need for effective indicators in selecting targeted therapies for advanced renal cell carcinoma (RCC).
- To explore molecular subclassification of tumors as a strategy for patient stratification and treatment selection.
- To identify potential new molecular targets for future RCC therapies.
Main Methods:
- Review of current literature on targeted therapies and biomarkers in advanced renal cell carcinoma.
- Analysis of the role of molecular tumor characteristics in predicting therapeutic benefits.
- Exploration of subclassification schemes for patient stratification.
Main Results:
- Biomarkers derived from therapeutic mechanisms and tumor biology show promise but require further investigation in advanced RCC.
- Molecular subclassification of tumors offers a potential strategy for stratifying patients based on expected therapeutic benefits.
- Development of tumor classification schemes may reveal novel molecular targets for future RCC therapies.
Conclusions:
- Molecular classification of tumors is essential for optimizing treatment selection in advanced renal cell carcinoma.
- This approach can enhance the effectiveness of current therapies and guide the development of future treatments.
- Personalized medicine strategies based on molecular profiling are key to improving outcomes for advanced RCC patients.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...